There is no direct evidence that ATF6 plays a role in drug-resistance, although one study found ATF6 to be an independent predictor of increased relapse and shorter survival in primary ESR1+ breast cancers treated with tamoxifen [32]. The gene discussed is ESR1; the disease is breast carcinoma.